Drugs for chronic hepatitis C infection recommendations report
Evidence-informed recommendations were developed by the CADTH Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. How should interferon-free direct-acting antiviral agent (DAA) regimens be listed for reimbursement for chronic hepatitis C (CHC) infection (genotypes 1 t...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
November 2015, 2015
|
| Edition: | Version 1.0 |
| Series: | CADTH therapeutic review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Evidence-informed recommendations were developed by the CADTH Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. How should interferon-free direct-acting antiviral agent (DAA) regimens be listed for reimbursement for chronic hepatitis C (CHC) infection (genotypes 1 to 6)?2. Should reimbursement of regimens for CHC infection be guided by fibrosis staging and limited to fibrosis stages e F2?3. Should re-treatment with a DAA regimen be reimbursed for patients with CHC infection who fail to achieve sustained virologic response (SVR) on another DAA regimen? |
|---|---|
| Physical Description: | 1 PDF file (iii, 28 pages) |